Development and characterization of a chronic implant mouse model for vagus nerve stimulation
- The Feinstein Institutes for Medical Research, United States
- University of Colorado Anschutz Medical Campus, United States
- New York University School of Medicine, United States
Abstract
Vagus nerve stimulation (VNS) suppresses inflammation and autoimmune diseases in preclinical and clinical studies. The underlying molecular, neurological, and anatomical mechanisms have been well characterized using acute electrophysiological stimulation of the vagus. However, there are several unanswered mechanistic questions about the effects of chronic VNS, which require solving numerous technical challenges for a long-term interface with the vagus in mice. Here, we describe a scalable model for long-term VNS in mice developed and validated in 4 research laboratories. We observed significant heart rate responses for at least 4 weeks in 60-90% of animals. Device implantation did not impair vagus-mediated reflexes. VNS using this implant significantly suppressed TNF levels in endotoxemia. Histological examination of implanted nerves revealed fibrotic encapsulation without axonal pathology. This model may be useful to study the physiology of the vagus and provides a tool to systematically investigate long-term VNS as therapy for chronic diseases modeled in mice.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 2, 3, and 4.
Article and author information
Author details
Ibrahim T Mughrabi
Funding
Defense Advanced Research Projects Agency (HR0011-17-2-0025)
- Stavros Zanos
United Therapeutics Corporation
- Stavros Zanos
Boston Scientific Corporation
- Yousef Al-Abed
Defense Advanced Research Projects Agency (HR0011-17-2-0051)
- Cristin Welle
Defense Advanced Research Projects Agency (N66001-17-2-4010)
- Robert C Froemke
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD088411)
- Robert C Froemke
Brain Research through Advancing Innovative Neurotechnologies (NS107616)
- Robert C Froemke
National Institute on Deafness and Other Communication Disorders (DC12557)
- Robert C Froemke
Howard Hughes Medical Institute (Faculty Scholarship)
- Robert C Froemke
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments complied with relevant ethical guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of the Feinstein Institutes for Medical Research (protocol numbers: 2016-029, 2017-010, and 2019-010) and University of Colorado Anschutz Medical Campus (protocol number: 00238).
Reviewing Editor
- Isaac M Chiu, Harvard Medical School, United States
Publication history
- Received: July 20, 2020
- Accepted: April 2, 2021
- Accepted Manuscript published: April 6, 2021 (version 1)
- Version of Record published: April 16, 2021 (version 2)
Copyright
© 2021, Mughrabi et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,985
- Page views
-
- 520
- Downloads
-
- 15
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Development and characterization of a chronic implant mouse model for vagus nerve stimulation
eLife 10:e61270.
https://doi.org/10.7554/eLife.61270
Further reading
-
- Immunology and Inflammation
Central tolerance ensures autoreactive T cells are eliminated or diverted to the regulatory T cell lineage, thus preventing autoimmunity. To undergo central tolerance, thymocytes must enter the medulla to test their TCRs for autoreactivity against the diverse self-antigens displayed by antigen presenting cells (APCs). While CCR7 is known to promote thymocyte medullary entry and negative selection, our previous studies implicate CCR4 in these processes, raising the question of whether CCR4 and CCR7 play distinct or redundant roles in central tolerance. Here, synchronized positive selection assays, 2-photon timelapse microscopy, and quantification of TCR-signaled apoptotic thymocytes, demonstrate that CCR4 and CCR7 promote medullary accumulation and central tolerance of distinct post-positive selection thymocyte subsets in mice. CCR4 is upregulated within hours of positive selection signaling and promotes medullary entry and clonal deletion of immature post-positive selection thymocytes. In contrast, CCR7 is expressed several days later and is required for medullary localization and negative selection of mature thymocytes. In addition, CCR4 and CCR7 differentially enforce self-tolerance, with CCR4 enforcing tolerance to self-antigens presented by activated APCs, which express CCR4 ligands. Our findings show that CCR7 expression is not synonymous with medullary localization and support a revised model of central tolerance in which CCR4 and CCR7 promote early and late stages of negative selection, respectively, via interactions with distinct APC subsets.
-
- Biochemistry and Chemical Biology
- Immunology and Inflammation
Genes associated with increased susceptibility to multiple sclerosis (MS) have been identified, but their functions are incompletely understood. One of these genes codes for the RNA helicase DExD/H-Box Polypeptide 39B (DDX39B), which shows genetic and functional epistasis with interleukin-7 receptor-α gene (IL7R) in MS-risk. Based on evolutionary and functional arguments, we postulated that DDX39B enhances immune tolerance thereby decreasing MS risk. Consistent with such a role we show that DDX39B controls the expression of many MS susceptibility genes and important immune-related genes. Among these we identified Forkhead Box P3 (FOXP3), which codes for the master transcriptional factor in CD4+/CD25+ T regulatory cells. DDX39B knockdown led to loss of immune-regulatory and gain of immune-effector expression signatures. Splicing of FOXP3 introns, which belong to a previously unrecognized type of introns with C-rich polypyrimidine tracts, was exquisitely sensitive to DDX39B levels. Given the importance of FOXP3 in autoimmunity, this work cements DDX39B as an important guardian of immune tolerance.
